Alerta

ANTI-TL1A ANTIBODY THERAPEUTIC METHODS

Resumen de: US20260078194A1

The present disclosure provides methods and compositions for determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.

METHOD OF TREATMENT

Resumen de: WO2024227232A1

The present invention relates generally to methods and compositions for treating and/or preventing an inflammatory bowel disease (IBD) and perianal fistulas, the method comprising the administration of therapeutic cells in the subject in need thereof.

DNA METHYLATION-BASED ALGORITHM TO DIAGNOSE IRRITABLE BOWEL SYNDROME AND OTHER GI CONDITIONS

Resumen de: WO2024227011A1

Blood-based genome-wide DNA methylation profiles are utilized to develop a reliable test to diagnose irritable bowel syndrome (IBS) versus inflammatory bowel disease (IBD), celiac disease and other gastrointestinal diseases that mimic IBS. These methods provide a means to rule out IBS and rule-in active IBD or celiac disease, as well as to rule-out active IBD and celiac disease, and to rule-in IBS.

COMPOSITIONS AND METHODS FOR IMMUNOLOGICAL TESTING OF STOOL

Resumen de: US20260060660A1

The present disclosure provides improved methods of processing a fecal sample by a human subject in which the fecal sample is collected at home and subsequently delivered to a medical diagnostics laboratory. As described herein, the means of collecting and processing the fecal sample can desirably reduce the number of steps undertaken by the human subject, including avoiding steps of removing or separating the fecal sample into multiple portions. Furthermore, the human subject does not have to perform an immunological test (e.g., a fecal immunochemical test (FIT) or an immunochemical fecal occult blood test (iFOBT)) at home.

METHODS FOR IDENTIFYING AND TREATING INFLAMMATORY BOWEL DISEASE

Resumen de: WO2026050646A1

This disclosure concerns metabolites that can be used to identify and characterize inflammatory bowel disease (IBD) as well as assess treatment for IBD.

AGENTS AND METHODS DIRECTED TO DISEASE-ASSOCIATED CELLS

Resumen de: WO2026047225A1

Provided herein are agents and methods suitable for the treatment of inflammatory diseases of the intestine. For instance, agents and methods are provided for the treatment of inflammatory bowel disease, Crohn's disease, ulcerative colitis, Celiac disease, and colitis-associated colorectal cancer.

PRÜFKÖRPER SOWIE VERFAHREN, PRÜFSTAND UND VERWENDUNG EINES PRÜFKÖRPERS ZUM ERMITTELN EINER MECHANISCHEN BELASTBARKEIT EINES UMHÜLLUNGSSYSTEMS FÜR ERDVERLEGTE STAHLROHRE

Resumen de: DE102024124516A1

Ein Prüfkörper (10), ibs. zum Eindrücken in einen zu prüfenden Gegenstand (12), der bsw. ein Umhüllungssystem für erdverlegte Stahlrohre (14) ist, hat die Gestalt eines Pyramidenstumpfes, Kegelstumpfes oder einer Halbkugelschicht mit einer Grundfläche (10g) und einer Deckfläche (10d), wobei- die Projektion der Deckfläche auf die Grundfläche innerhalb der Grundfläche liegt;- die Deckfläche parallel zu der Grundfläche ist.Ein Verfahren zum Ermitteln einer mechanischen Belastbarkeit eines Umhüllungssystems für erdverlegte Stahlrohre umfasst, dass- der Prüfkörper mit der Deckfläche voran von außen gegen das Umhüllungssystem gemäß einem vorbestimmten Wegverlauf und/oder Kraftverlauf gedrückt wird;- die Eindringtiefe des Prüfkörpers in das Umhüllungssystem erfasst wird;- die Belastbarkeit abhängig von der erfassten Eindringtiefe ermittelt wird.Ein Prüfstand (16) zum Ermitteln einer mechanischen Belastbarkeit eines Umhüllungssystems für erdverlegte Stahlrohre umfasst- ein Haltesystem (18);- eine Materialprüfmaschine (20), die den Prüfkörper mit der Deckfläche voran gegen das Umhüllungssystem drücken kann;- eine Messeinrichtung (22), die die Eindringtiefe des Prüfkörpers in das Umhüllungssystem erfassen kann;- eine Steuereinrichtung (24), die gemäß dem Verfahren die Materialprüfmaschine und die Messeinrichtung ansteuern und die Belastbarkeit ermitteln kann.Der Prüfkörper wird zum Ermitteln der mechanischen Belastbarkeit gemäß dem Verfahre

Methods and compositions for prediction of response to a therapy of an inflammatory bowel disease

Resumen de: AU2026201149A1

Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn’s disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and 5 kits for predicting the response to the therapy of the inflammatory bowel disease. eb e b

Ultrahigh-affinity nucleic acid aptamer for specifically recognizing CD4 protein by using Re-SILEX technology

Resumen de: CN121592655A

The invention discloses a method for screening an ultrahigh-affinity nucleic acid aptamer for specifically recognizing CD4 protein by using a Re-SILEX technology, and belongs to the technical field of nucleic acid. The invention aims to solve the technical problem of how to effectively detect or target CD4 protein. In order to solve the technical problem, the invention provides a nucleic acid aptamer, the nucleic acid aptamer is at least one of nucleic acid aptamers with the name of CD4rzj-4a, CD4rzj-2a, CD4rzj-5a, CD4rzj-6a, CD4rzj-1b, CD4rzj-3a and CD4rzj-1a, and the nucleic acid aptamer CD4rzj-4a is a nucleic acid molecule with the nucleotide sequence of SEQ ID NO: 6. The aptamer provided by the invention has excellent specific binding force, and has important application potential in the field of CD4 detection or targeting.

Nano-enzyme coating recombinant probiotics as well as preparation method and application thereof

Resumen de: CN121592569A

The invention discloses nano-enzyme coating recombinant probiotics as well as a preparation method and application thereof, and belongs to the technical field of biotechnology and nano medicine. According to the invention, engineered Escherichia coli Nissle 1917 (ECN (DE3)) is taken as a host, and glutathione peroxidase (GPX) and glutathione reductase (GR) genes are over-expressed through a genetic engineering means, so that an efficient antioxidant enzyme system is constructed. And sequentially modifying chitosan and cerium dioxide nano-enzyme (CNP) on the surfaces of the thalli by using an electrostatic layer-by-layer self-assembly technology to form a protective coating. The nano-enzyme coating significantly improves the survival rate of the recombinant probiotics in severe environments such as simulated gastric acid (pH 2.5) and bile salt (0.3%), and enhances the ability of the recombinant probiotics to remove reactive oxygen species (ROS), including hydrogen peroxide, superoxide anions, hydroxyl free radicals and DPPH free radicals.

A METHOD OF IMMUNE MODULATION BY MODULATING ABCF1

Resumen de: US20260099855A1

0000 Systems and methods are provided for authenticating, verifying, and tracking physical and digital assets through an integrated framework combining artificial intelligence, multi-sensor fusion, blockchain provenance, and quantum-secure processing. The system establishes a continuous provenance loop where real-time live capture, multi-sensor scanning, and expanded identifiers are analyzed by an AI decision engine to generate a unique multi-modal fingerprint. 0000 This fingerprint is encoded into one or more machine-readable identifiers immutably recorded on a blockchain ledger. A Genesis Certificate of Authenticity (COA) anchors the item's origin, ownership, and transfer history. Subsequent resales or transfers trigger smart contracts that automate royalty distribution and provenance updates. The value captured through these processes can be monetary, such as currency or royalties, or intrinsic, such as positive social impact derived from verified actions or good deeds. Quantum acceleration enhances pattern matching, anomaly detection, and cryptographic resilience across industries.

METHODS OF DISEASE ACTIVITY PROFILING FOR PERSONALIZED THERAPY MANAGEMENT

Resumen de: US20260099855A1

0000 Systems and methods are provided for authenticating, verifying, and tracking physical and digital assets through an integrated framework combining artificial intelligence, multi-sensor fusion, blockchain provenance, and quantum-secure processing. The system establishes a continuous provenance loop where real-time live capture, multi-sensor scanning, and expanded identifiers are analyzed by an AI decision engine to generate a unique multi-modal fingerprint. 0000 This fingerprint is encoded into one or more machine-readable identifiers immutably recorded on a blockchain ledger. A Genesis Certificate of Authenticity (COA) anchors the item's origin, ownership, and transfer history. Subsequent resales or transfers trigger smart contracts that automate royalty distribution and provenance updates. The value captured through these processes can be monetary, such as currency or royalties, or intrinsic, such as positive social impact derived from verified actions or good deeds. Quantum acceleration enhances pattern matching, anomaly detection, and cryptographic resilience across industries.

USE OF RIFAXIMIN IN SUBJECTS HAVING DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME

Resumen de: US20260099855A1

0000 Systems and methods are provided for authenticating, verifying, and tracking physical and digital assets through an integrated framework combining artificial intelligence, multi-sensor fusion, blockchain provenance, and quantum-secure processing. The system establishes a continuous provenance loop where real-time live capture, multi-sensor scanning, and expanded identifiers are analyzed by an AI decision engine to generate a unique multi-modal fingerprint. 0000 This fingerprint is encoded into one or more machine-readable identifiers immutably recorded on a blockchain ledger. A Genesis Certificate of Authenticity (COA) anchors the item's origin, ownership, and transfer history. Subsequent resales or transfers trigger smart contracts that automate royalty distribution and provenance updates. The value captured through these processes can be monetary, such as currency or royalties, or intrinsic, such as positive social impact derived from verified actions or good deeds. Quantum acceleration enhances pattern matching, anomaly detection, and cryptographic resilience across industries.

Application of E3 ubiquitin ligase RNF219 in preventing or treating inflammatory diseases

Resumen de: CN121570596A

The invention relates to the technical field of biological medicines, in particular to application of E3 ubiquitin ligase RNF219 in preventing or treating inflammatory diseases. The invention provides an application of a substance for inhibiting the activity of RNF219 protein or a substance for reducing the content of RNF219 protein in preparation of drugs for preventing or treating inflammatory diseases, especially drugs for preventing or treating sepsis and colitis. According to the application, a mouse acute infection model is constructed to prove that RNF219 defect inhibits the inflammatory reaction degree and inflammatory injury induced by LPS (Lipopolysaccharide); in a mouse with DSS-induced colitis, the RNF219 defect can delay the disease progress of the mouse colitis and improve the inflammatory phenotype of the mouse. Therefore, the function of the RNF219 in natural immune response is defined, and the RNF219 has important scientific significance on prevention and treatment of immune inflammation related diseases such as sepsis and inflammatory bowel diseases.

基于肠脑轴调控的治疗剂的生物芯片筛选方法及其应用

Resumen de: CN121575078A

本发明涉及生物医学工程，公开了一种基于肠脑轴调控的治疗剂的生物芯片筛选方法及其应用。该筛选方法包括以下步骤：采用表面经仿生化处理的超表面等离子共振生物芯片，进行肠壁细胞培养或者小胶质细胞培养获得肠壁细胞贴壁或者小胶质细胞贴壁的芯片板，在细胞贴壁的芯片板内加入含化疗药物或脂多糖的培养基进行培养I，再除去培养基、加入待测治疗剂进行培养II得到培养液，检测所述培养液中肠壁细胞或者小胶质细胞的细胞修复效果；筛选获得对肠壁细胞和/或小胶质细胞具有修复作用的治疗剂。该筛选方法能够从多个待测治疗剂中高效、准确地筛选出兼具肠道调节与神经保护双重功效的治疗剂，且能够实现无标记、实时在线动态监测与探究治疗剂和细胞的相互作用情况。

ANTI-TREM-1 ANTIBODIES AND USES THEREOF

Resumen de: US20260055183A1

Provided herein are methods of identifying subjects suitable for an anti-TREM-1 antibody (i.e., antagonistic anti-TREM-1 antibody) treatment comprising measuring an expression level of a TREM-1 associated gene. Also disclosed herein are methods of determining efficacy of an anti-TREM-1 antibody comprising measuring an expression level of a TREM-1 associated gene. Methods of identifying non-responder to a standard of care treatment and methods of treating a disease or disorder (e.g., inflammatory bowel disease) with an anti-TREM-1 antibody are also disclosed.

SYSTEMS AND METHODS FOR PREDICTING RESPONSE TO ANTI-TNF THERAPIES

Resumen de: US20260057960A1

Disclosed herein are methods and systems for administering therapy to subjects who have been determined to display or not display a gene expression response signature established to distinguish between responsive and non-responsive prior subjects who have received the therapy. The subject and prior subjects may suffer from a disease, disorder, or condition for which it is desired to predict whether the subject will respond to the therapy. In an aspect, the disease, disorder, or condition may be an autoimmune disorder such as ulcerative colitis. The subject may be administered an anti-TNF therapy or an alternative to anti-TNF therapy based upon predictions provided by methods and systems described herein.

METHOD, PROGRAM, AND APPARATUS FOR DETECTING SMALL INTESTINAL BACTERIAL OVERGROWTH

Resumen de: US20260053426A1

Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data representing a time series of readings from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject, identifying the data corresponding to timing of passage through the small intestine, and determining whether or not the data indicates presence of SIBO.

PREDICTING NON-RESPONSIVENESS OF IBD PATIENTS

Resumen de: WO2024224133A1

Predicting non-responsiveness of IBD patients The present invention relates to an in vitro method for predicting the responsiveness of an IBD patient to a therapy with an intracellularly acting immunosuppressive agent of interest, wherein a sample is provided from the IBD patient at an initial period of a treatment with the immunosuppressive agent of interest, said sample comprising effector mononuclear cells, and responsiveness is predicted from the difference between a multidrug ABC transporter activity level in the effector mononuclear cells in said sample and a reference transporter activity level. The method is useful in a treatment of IBD, e.g. in monitoring the progress of the disease or in a decision on a shift from an initial treatment with an agent to another agent like csDMARD or tsDMARD.

基于荧光探针的ATP水解酶抗体高效筛选法

Resumen de: CN121559077A

本发明公开了基于荧光探针的ATP水解酶抗体高效筛选法，包括生化体系和细胞体系两种检测方案，在生化体系中，通过定量ENTPD2蛋白水解ATP后剩余量，直接计算抗体抑制率；在细胞体系中，利用过表达ENTPD2的细胞验证抗体对跨膜酶的抑制功能。该生化体系方法无需抗体纯化，仅需5-15μL B细胞上清液即可完成初筛，筛选准确度高(细胞体系可用作验证筛选得到的抗体)，与体内药效结果一致，适用于抗ENTPD2抗体药物的开发，显著降低研发成本。

Crohn disease auxiliary prediction method and device based on machine learning

Resumen de: CN121565478A

The invention relates to a Crohn disease auxiliary prediction method based on machine learning. The method comprises the following steps: obtaining related prediction data of a user; whether missing items exist in the user related prediction data is judged, if yes, an alarm is given to remind a user to supplement, if the user confirms that supplement cannot be carried out, self-adaptive complementation is carried out, and finally to-be-predicted data is formed; inputting the to-be-predicted data into a pre-established Crohn disease auxiliary prediction model, and outputting a prediction result by the Crohn disease auxiliary prediction model; the Crohn disease auxiliary prediction model is constructed based on an XGBoost model; and visually displaying the prediction result to inform a user. According to the method, when the data input by the user is missing, the user can be reminded to supplement, if the data cannot be supplemented, self-adaptive complementation is carried out, the prediction accuracy of the model is improved, Crohn disease risk prediction can be carried out according to the existing indexes of the patient, the user can conveniently find related risks in time, and the user experience is improved. And the diagnosis and treatment efficiency of the user is improved.

潰瘍性大腸炎に関与する遺伝子の抗ＩＬ－２３Ｐ１９抗体調節

Resumen de: US2024254217A1

The present disclosure generally relates to methods of treating and diagnosing ulcerative colitis. The methods are particularly suitable for treating and diagnosing a specific sub-group of patients with ulcerative colitis. The methods are also particularly suitable for treating and diagnosing urgency in a patient having or suspected of having ulcerative colitis. The methods are also particularly suitable for treating and diagnosing stool frequency and bowel urgency in a patient having or suspected of having ulcerative colitis.

Ｃ４Ａ３－ＨＮＥ及びＣ４Ａ４－ＨＮＥアッセイ

Resumen de: WO2024160832A1

Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.

Application of Slc36a1 agonist in preparation of medicine for preventing and/or treating colitis

Resumen de: CN121512985A

The invention provides application of an Slc36a1 agonist in preparation of a medicine for preventing and/or treating colitis, and belongs to the technical field of biology. According to the invention, 4-GBA or sarcosine is applied to a colitis model mouse, and clinical and histological phenotypes of DSS-induced colitis can be significantly improved. According to experiments of colonic organs and mice, 4-GBA enhances intestinal mucosal barrier and promotes intestinal homeostasis by up-regulating Slc36a1. According to the invention, 4-GBA or sarcosine molecules targeting Slc36a1 are taken as a core, and the limitation of an existing treatment strategy is broken through by synchronously solving a linkage mechanism of stem cell regeneration-goblet cell differentiation-mucous barrier repair.

BIOMARKERS OF INFLAMMATORY BOWEL DISEASES (Machine-translation by Google Translate, not legally binding)

Nº publicación: ES3055703A1 13/02/2026

Solicitante:

FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIV DE LA PRINCESA [ES]
CONSORCIO CENTRO DE INVESTIG BIOMEDICA EN RED [ES]
FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA,
CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED

Resumen de: ES3055703A1

Biomarkers of inflammatory bowel diseases. The present invention relates to a method for early determination of whether a subject has an inflammatory bowel disease, comprising determining the expression product level of at least one biomarker, from a biological sample of a subject, selected from: ATRN, PRDX4, MOAB and AZU1. (Machine-translation by Google Translate, not legally binding)